Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2 CAD | -4.76% | -3.85% | -25.93% |
Apr. 17 | NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update | MT |
Apr. 17 | NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
William Radvak
FOU | Founder | 61 | 17-01-18 |
Michael Kelly
CEO | Chief Executive Officer | 59 | 23-04-09 |
Bill Adams
DFI | Director of Finance/CFO | 62 | 20-02-23 |
Daniel Mikol
CTO | Chief Tech/Sci/R&D Officer | - | 21-05-04 |
Adam Rogers
BRD | Director/Board Member | - | 22-07-13 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Randall Kaye
BRD | Director/Board Member | 61 | 20-10-27 |
Brian Bayley
BRD | Director/Board Member | 71 | 18-05-15 |
William Radvak
FOU | Founder | 61 | 17-01-18 |
Michael Kelly
CEO | Chief Executive Officer | 59 | 23-04-09 |
Harold Punnett
FOU | Founder | 67 | 17-01-18 |
John Thompson
BRD | Director/Board Member | 57 | 22-04-12 |
John Ruffolo
BRD | Director/Board Member | - | 23-10-16 |
Glenn Ives
BRD | Director/Board Member | 62 | 21-08-31 |
Adam Rogers
BRD | Director/Board Member | - | 22-07-13 |
Director/Board Member | - | 21-08-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 69,927,649 | 53,814,835 ( 76.96 %) | 0 | 76.96 % |
Company contact information
NervGen Pharma Corp.
112-970 Burrard Street Unit 1290
V6Z 2R4, Vancouver
+778-731-1711
http://www.nervgen.comSector
Sales per region
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-25.93% | 103M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+37.29% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- NGEN Stock
- Company NervGen Pharma Corp.